Amgen in deal to commercialise therapeutic biological products

Amgen has signed a deal with US firm Human Genome Sciences under which it will acquire exclusive worldwide rights to develop and commercialise therapeutic biological products.

The products are for human use based on a human gene discovered by Human Genome Sciences that may have potential applications in autoimmune diseases, immune deficiencies or suppression, and cancer, Human Genome Sciences said in a statement.

Amgen also acquired non-exclusive worldwide rights for the development and commercialisation of diagnostic products for human use based on the same gene.

H Thomas Watkins, president and chief executive officer, Human Genome
Sciences, said, ” This agreement is one more step in our monetisation of Human Genome Sciences assets and in providing access to our technology to those companies who share our goal of developing gene-based therapeutic and diagnostic products for use in the treatment of serious diseases.”

© Adfero Ltd